161 related articles for article (PubMed ID: 22415059)
1. Nephrogenic adenoma of the urinary tract: a review.
Alexiev BA; LeVea CM
Int J Surg Pathol; 2012 Apr; 20(2):123-31. PubMed ID: 22415059
[TBL] [Abstract][Full Text] [Related]
2. Nephrogenic adenoma: an update on an innocuous but troublesome entity.
Rahemtullah A; Oliva E
Adv Anat Pathol; 2006 Sep; 13(5):247-55. PubMed ID: 16998318
[TBL] [Abstract][Full Text] [Related]
3. S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
Cossu-Rocca P; Contini M; Brunelli M; Festa A; Pili F; Gobbo S; Eccher A; Mura A; Massarelli G; Martignoni G
Am J Surg Pathol; 2009 Jul; 33(7):1031-6. PubMed ID: 19384190
[TBL] [Abstract][Full Text] [Related]
4. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
Tong GX; Weeden EM; Hamele-Bena D; Huan Y; Unger P; Memeo L; O'Toole K
Am J Surg Pathol; 2008 Sep; 32(9):1380-7. PubMed ID: 18670350
[TBL] [Abstract][Full Text] [Related]
5. [Nephrogenic adenoma of the bladder. Morphological and immunophenotypic study with particular attention to differential diagnosis].
Isimbaldi G; Di Nuovo F; Sironi M; Catania G; Bonacina R; Privitera O; Spinelli M
Pathologica; 1999 Jun; 91(3):192-7. PubMed ID: 10536465
[TBL] [Abstract][Full Text] [Related]
6. Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma.
Hansel DE; Nadasdy T; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1231-7. PubMed ID: 17667548
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the immunophenotype of nephrogenic adenoma.
Fromont G; Barcat L; Gaudin J; Irani J
Am J Surg Pathol; 2009 Nov; 33(11):1654-8. PubMed ID: 19730362
[TBL] [Abstract][Full Text] [Related]
8. Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma.
Herawi M; Drew PA; Pan CC; Epstein JI
Hum Pathol; 2010 Apr; 41(4):594-601. PubMed ID: 20060152
[TBL] [Abstract][Full Text] [Related]
9. Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma.
Skinnider BF; Oliva E; Young RH; Amin MB
Am J Surg Pathol; 2004 Jun; 28(6):701-5. PubMed ID: 15166661
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
Xiao GQ; Burstein DE; Miller LK; Unger PD
Arch Pathol Lab Med; 2006 Jun; 130(6):805-10. PubMed ID: 16740031
[TBL] [Abstract][Full Text] [Related]
11. Flat pattern of nephrogenic adenoma: previously unrecognized pattern unveiled using PAX2 and PAX8 immunohistochemistry.
Piña-Oviedo S; Shen SS; Truong LD; Ayala AG; Ro JY
Mod Pathol; 2013 Jun; 26(6):792-8. PubMed ID: 23328975
[TBL] [Abstract][Full Text] [Related]
12. Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin.
Sung MT; Zhang S; MacLennan GT; Lopez-Beltran A; Montironi R; Wang M; Tan PH; Cheng L
Clin Cancer Res; 2008 Apr; 14(7):1947-55. PubMed ID: 18381932
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3.
McDaniel AS; Chinnaiyan AM; Siddiqui J; McKenney JK; Mehra R
Am J Surg Pathol; 2014 Dec; 38(12):1664-71. PubMed ID: 24921643
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic Adenoma of the Prostatic Urethra Mimicking Prostatic and Bladder Carcinomas.
Beeter MC; Fazili T; Yeh YA
Cureus; 2023 Mar; 15(3):e35998. PubMed ID: 37041930
[TBL] [Abstract][Full Text] [Related]
15. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
16. Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics.
Shanks JH; Iczkowski KA
Histopathology; 2009 Jun; 54(7):885-900. PubMed ID: 19178589
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic adenoma of the urinary tract: A 6-year single center experience.
Turcan D; Acikalin MF; Yilmaz E; Canaz F; Arik D
Pathol Res Pract; 2017 Jul; 213(7):831-835. PubMed ID: 28554748
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic adenoma: an immunohistochemical analysis using biotin-free methods.
Ortiz-Rey JA; Antón-Badiola I; Pérez-Pedrosa A; Peteiro-Cancelo Á; González-Carreró J
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):386-91. PubMed ID: 22495376
[TBL] [Abstract][Full Text] [Related]
19. Clear cell adenocarcinoma of the lower urinary tract: cytopathologic characteristics and differential diagnoses.
Whitworth SA; Subhawong AP; Rosenthal DL; Ali SZ
Cancer Cytopathol; 2012 Oct; 120(5):308-12. PubMed ID: 22517612
[TBL] [Abstract][Full Text] [Related]
20. Nephrogenic adenoma identified on urine cytology using PAX-2 immunostaining.
Herlitz LC; Tong GX; Hamele-Bena D; Greenebaum E
Diagn Cytopathol; 2008 Jan; 36(1):47-9. PubMed ID: 18064687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
